Literature DB >> 9504391

Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes.

J Cartmell1, G Adam, S Chaboz, R Henningsen, J A Kemp, A Klingelschmidt, V Metzler, F Monsma, H Schaffhauser, J Wichmann, V Mutel.   

Abstract

1. The binding of the new selective group II metabotropic glutamate receptor radioligand, [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine ([3H]-DCG IV), was characterized in rat mGlu2 receptor-transfected CHO cell membranes. 2. [3H]-DCG IV binding was pH-dependent, but was not sensitive to temperature. Saturation analysis showed the presence of a single binding site, with a Kd value of 160 nM and a Bmax value of 10 pmol mg(-1) protein. Binding was not sensitive to Na+-dependent glutamate uptake blockers or Cl-dependent glutamate binding inhibitors. Furthermore, up to concentrations of 1 mM, the glutamate ionotropic receptor agonists, N-methyl-D-aspartic acid (NMDA), (S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate, did not affect [3H]-DCG IV binding. 3. Of the compounds observed to inhibit [3H]-DCG IV binding, the most potent were the recently described selective group II agonist, (+)-2-aminobicyclo-[3.1.0]hexane-2,6-dicarboxylate (LY 354740; Ki value 16 nM) and antagonist, 2-amino-2-(2-carboxycyclopropan-1-yl)-3-(dibenzopyran-4-yl) propanoic acid (LY 341495; Ki value 19 nM). As expected, for a G-protein-coupled receptor, guanosine-5'-O-(3-thiotriphosphate) (GTPgammaS) inhibited [3H]-DCG IV binding in a concentration-dependent manner, with an IC50 value of 12 nNM. 4. A highly significant correlation was observed between the potencies of compounds able to inhibit [3H]-DCG IV binding and potencies obtained for agonist activity in a GTPgamma35S binding functional assay. In addition, these studies identified a number of compounds with previously unknown activity at mGlu2 receptors, including L(+)-2-amino-3-phosphonopropionic acid (L-AP3), L(+)-2-amino-5-phosphonopentanoic acid (L-AP5), 3-((RS)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (R-CPP), N-acetyl-L-aspartyl-L-glutamic acid (NAAG) and (RS)-alpha-methylserine-O-phosphate (MSOP).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9504391      PMCID: PMC1565198          DOI: 10.1038/sj.bjp.0701647

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  Developmental regulation of hippocampal excitatory synaptic transmission by metabotropic glutamate receptors.

Authors:  F M Ross; J Cassidy; M Wilson; S N Davies
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

2.  Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ-46281222.

Authors:  Maarten L J Doornbos; Laura Pérez-Benito; Gary Tresadern; Thea Mulder-Krieger; Ilse Biesmans; Andrés A Trabanco; Jose María Cid; Hilde Lavreysen; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2016-01-13       Impact factor: 8.739

Review 3.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

4.  Structures of the extracellular regions of the group II/III metabotropic glutamate receptors.

Authors:  Takanori Muto; Daisuke Tsuchiya; Kosuke Morikawa; Hisato Jingami
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-26       Impact factor: 11.205

5.  Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).

Authors:  Michael P Johnson; David Barda; Thomas C Britton; Renee Emkey; William J Hornback; G Erik Jagdmann; David L McKinzie; Eric S Nisenbaum; Joseph P Tizzano; Darryle D Schoepp
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 6.  Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators.

Authors:  Douglas J Sheffler; Anthony B Pinkerton; Russell Dahl; Athina Markou; Nicholas D P Cosford
Journal:  ACS Chem Neurosci       Date:  2011-04-12       Impact factor: 4.418

7.  N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia.

Authors:  Frank Jessen; Natascha Fingerhut; Alois M Sprinkart; Kai-Uwe Kühn; Nadine Petrovsky; Wolfgang Maier; Hans-H Schild; Wolfgang Block; Michael Wagner; Frank Träber
Journal:  Schizophr Bull       Date:  2011-09-12       Impact factor: 9.306

8.  Type 2 metabotropic glutamate receptor (mGluR2) fails to negatively couple to cGMP in stably transfected cells.

Authors:  Barbara Wroblewska; Iga N Wegorzewska; Tomasz Bzdega; Joseph H Neale
Journal:  Neurochem Int       Date:  2010-11-27       Impact factor: 3.921

9.  Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats.

Authors:  Xiao-Qing Peng; Jie Li; Eliot L Gardner; Charles R Ashby; Ajit Thomas; Krystyna Wozniak; Barbara S Slusher; Zheng-Xiong Xi
Journal:  Eur J Pharmacol       Date:  2009-10-31       Impact factor: 4.432

10.  Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism.

Authors:  Zheng-Xiong Xi; Xia Li; Xiao-Qing Peng; Jie Li; Lauren Chun; Eliot L Gardner; Ajit G Thomas; Barbara S Slusher; Charles R Ashby
Journal:  J Neurochem       Date:  2009-11-06       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.